Atreca, Inc.

96 articles with Atreca, Inc.

• Atreca to Present at Two Upcoming Investor Conferences - Nov. 14, 2019

  11/14/2019

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced that it will present at two upcoming investor conferences

• Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

  11/12/2019

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced financial results for the third quarter ended September 30, 2019, and provided an overview of recent developments.

• Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/5/2019

  Atreca, Inc. announced that it will present a poster describing preclinical evaluations of ATRC-101 at the upcoming 34th Annual Meeting of the Society for Immunotherapy of Cancer, to be held from November 6-10 in National Harbor, MD.

• Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

  8/13/2019

  Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, and provided an overview of Atreca’s recent developments.

• Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

  7/11/2019

  Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel.

• 

  Six Biotech Companies with IPOs This Week

  6/21/2019

  This week marked initial public offering news from six biopharma companies. Here’s a look.

• Atreca Announces Pricing of Initial Public Offering

  6/19/2019

  Atreca, Inc.(Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a price to the public of $17.00 per share.

• Atreca to Present at the Cowen and Company Annual Health Care Conference

  3/4/2019

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that John A. Orwin, President and Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference.

• Atreca Announces Retirement of Susan Berland and Appoints Herb Cross as Chief Financial Officer

  2/25/2019

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the retirement of Susan Berland, Executive Vice President and Chief Financial Officer (CFO), and the appointment of Herb Cross, an accomplished senior financial executive, as her successor.

• Atreca to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that John A. Orwin, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 1:30 p.m. Pacific Standard Time in San Francisco, CA.

• Atreca to Present Analyses of Active B Cell Responses in Nearly 200 Cancer Patients Leading to Identification of More Than 1,000 Antibodies Targeting Non-Autologous Tumor

  11/15/2018

  Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today a presentation describing use of the Company’s proprietary Discovery Engine, featuring the Company’s Immune Repertoire Capture® (IRC™) technology,

• Atreca to Present Data Further Demonstrating Ability of the Company’s Discovery Engine to Identify Patient-Derived Antibodies that Target Non-Autologous Tumor Tissue

  11/6/2018

  Study to be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

• Atreca Raises $125 Million to Expand its Preclinical Pipeline and Advance its First Program into Clinical Trials

  9/12/2018

  Atreca, Inc. announced today the closing of an oversubscribed $125 million financing.

• Atreca to Present Immuno-Oncology Research Findings at 2018 World Preclinical Congress

  6/7/2018

  Atreca, Inc. announced today that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Atreca, will deliver a presentation during the 2018 World Preclinical Congress (WPC) Annual Meeting.

• Atreca to Present at the Jefferies 2018 Global Healthcare Conference

  5/30/2018

  Atreca, Inc. announced that John A. Orwin, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.

• Atreca Announces Publication of HIV Research in Cell

  5/3/2018

  May 3, 2018 15:00 UTC Atreca Announces Publication of HIV Research in Cell Research Findings Promise New Avenues for Anti-Viral Therapeutic Development REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today publication of research focused on HIV that was enabled by Atreca’s

• Atreca Announces John A. Orwin Appointed President and CEO

  4/19/2018

  Atreca Co-Founder Dr. Tito A. Serafini Will Serve as Chief Strategy Officer Lead Anti-Cancer Candidate Slated to Enter Clinical Testing in 2019

• Atreca to Participate in Immunotherapy Showcase at the 2018 Precision Medicine World Conference

  1/19/2018

  Atreca announced today that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer, will deliver a presentation on the Company’s lead programs in immuno-oncology as part of the Immunotherapy Showcase during the 2018 Precision Medicine World Conference on Wednesday, January 24, 2018, at 1:45 PM PT in Mountain View, CA.

• Atreca Reports on Tumor-Fighting Responses in B Cells from Patients with Non-Progressing Metastatic Cancers

  12/19/2017

  Atreca announced today publication of noteworthy results in preclinical cancer research enabled by Atreca’s Immune Repertoire Capture® (IRC™) technology.

• Atreca Nabs $35 Million To Advance Novel Cancer Immunotherapies

  8/17/2017